Research
Thinking up ways to better address future public health emergencies, the Biomedical Advanced Research and Development Authority’s (BARDA) Division of Research, Innovation and Ventures (DRIVe) has expanded a partner program focused on technology development to include digital health tools and... Read More »
The National Institutes of Health (NIH) began a Phase 2 clinical trial last week to investigate any antibody response generated by an extra dose of authorized/approved COVID-19 vaccines among patients with autoimmune disease who experienced no response from a previous vaccine regimen.
The... Read More »
According to a new paper from the nonprofit Nuclear Threat Initiative (NTI), artificial intelligence in nuclear weapons systems is a neutral wash of possibilities -- but it also appears inevitable, and as a result, immediate action is needed to balance benefits and risks while the technology is... Read More »
New voices were added to the United States Department of Health and Human Services’ (HHS) Tick-Borne Disease Working Group this week, filling positions left vacant by public members looking to workshop ideas on how best to counter rising cases of tick-borne illnesses.
In all, seven new members... Read More »
INOVIO received the green light for phase three of its INNOVATE Phase 2/3 clinical trial of INO-4800 last week, allowing it to proceed with efficacy evaluation of its COVID-19 DNA vaccine candidate in Brazil.
Alongside its partner, Advaccine Biopharmaceuticals Suzhou Co., Ltd., INOVIO intends to... Read More »
The largest ever Lassa Fever study in West Africa secured the means of testing this week, thanks to a contract between the Coalition for Epidemic Preparedness Innovations (CEPI) and Zalgen Labs LLC, which will supply antibody testing kits for up to 7,000 participants.
Zalgen, a biotechnology... Read More »
New data released by Johnson & Johnson this week showed that using its single-shot COVID-19 vaccine as a booster for the previously vaccinated could provide as much as a nine-fold increase in antibodies for patients at least 18 years old.
The news follows interim reports from July, published in... Read More »
Through publication of data in Vaccine, this week Soligenix showcased the capabilities of its filovirus vaccine platform to formulate and provide heat stabilization for multiple antigen combinations of vaccine candidates: monovalent, bivalent, and trivalent.
The single-vial platform project was... Read More »
A 210-person Phase 2 clinical trial for the COVID-19 vaccine candidate, ABNCoV2, began this week to determine its potential as a booster vaccine for those who have either caught the disease previously or been otherwise vaccinated.
Licensed by Bavarian Nordic A/S and developed by AdaptVac, the... Read More »
Results of a Phase 3 clinical trial have shown that AstraZeneca’s antibody combination for COVID-19, AZD7442, cuts the risk of symptomatic COVID-19 cases by 77 percent for at least three months.
That is dependent on the treatment being taken prior to infection. However, the antibodies used in... Read More »
With the formation of a new Scientific Advisory Group for the Origins of Novel Pathogens (SAGO), the World Health Organization (WHO) is calling for experts to lend their knowledge on the origins of pathogens with wide-reaching potential.
This multidisciplinary group will consist of up to 25... Read More »
While key federal agencies prepared interagency response plans and conducted 74 interagency exercises from 2009 through 2019 to prepare for and respond to a wide variety of biological incidents, the Government Accountability Office (GAO) recently determined that the agencies weren’t on the same... Read More »
According to preclinical data produced by Soligenix, Inc. this week, positive, effective results have been demonstrated by multiple filovirus vaccine candidates.
In collaboration with the University of Hawaiʻi at Mānoa, Soligenix’s vaccines proved capable against three potentially deadly... Read More »
Utilizing initial funding from the American Rescue Plan, the U.S. Centers for Disease Control and Prevention (CDC) unveiled plans this week for a new Center for Forecasting and Outbreak Analytics, focused on forecasts of disease outbreaks and analytics for public health.
The new center will be... Read More »
The U.S. Department of Homeland Security (DHS) Science and Technology Directorate (S&T) recently composed an Environmental Assessment draft regarding a New York City aerosol particle behavior study.
“This study is part of the Department’s ongoing commitment to public safety against the... Read More »
Federal Emergency Management Agency (FEMA) announced this week that it has launched the National Risk Index, designed to provide guidance regarding nationwide natural hazard risks.
Authorities indicated the resource also seeks to inform and educate communities as a means of helping to reduce the... Read More »
The National Institutes of Health (NIH) announced this week that it will award approximately $53 million in annual funding across the next five years to 10 research organizations currently pursuing HIV cure research.
“June marked the 40th anniversary of the first reported U.S. cases of what... Read More »
As part of a new agreement with Gritstone bio, Inc., the Coalition for Epidemic Preparedness Innovations (CEPI) will provide up to $20.6 million to support the development of a new, self-amplifying mRNA vaccine candidate for the growing number of COVID-19 variants.
These funds will cover a... Read More »
A preclinical study conducted on non-human primates and published this week showed potential in a second-generation mRNA COVID-19 vaccine candidate, CV2CoV, created by the joint efforts of biopharmaceutical companies CureVac N.V. and GSK.
Among cynomolgus macaques, the new candidate -- an... Read More »
With diagnostic testing as important as ever in the battle to contain COVID-19, researchers from various institutions under the umbrella of the National Institutes of Health (NIH) have banded together to create a new sample preparation method for detecting SARS-CoV-2.
The collaboration has... Read More »
The specialty vaccine firm Valneva SE has initiated a Phase 3 trial for its COVID-19 vaccine candidate, VLA2001.
VLA2001-304 seeks to generate data in the elderly and is designed to potentially enable variant-bridging through immune-comparability. Study data is slated to complement ongoing... Read More »
The Government Accountability Office (GAO) has issued seven recommendations to the National Nuclear Security Administration (NSSA) regarding lithium activities.
The analysis and recommendations stem from NSSA facilities deteriorating and the agency proposing a new facility to meet lithium... Read More »
According to a new manuscript published in Science last week, the majority of people given Moderna Inc.’s COVID-19 vaccine maintained antibodies not just against SARS-CoV-2, but against many of its variants of concern, for six months after a second dose.
The two-dose vaccine has been... Read More »
The Defense Advanced Research Projects Agency recently selected three teams to support the Harnessing Enzymatic Activity for Lifesaving Remedies (HEALR) program.
The HEALR program, which bolsters chemical biology, medicinal chemistry, and microbiology expertise to transform the field of... Read More »
Groups of medical experts this week proposed a standardized definition for defining and evaluating placental SARS-CoV-2 infections to optimize both clinical care and new research, as well as the pursuit of COVID-19 vaccinations for pregnant individuals.
The first came from a panel of experts... Read More »
Regulatory approval was granted for two new clinical trials of INO-4800 in China this week, allowing its creator INOVIO and its partners Advaccine Biopharmaceuticals Suzhou Co. Ltd. and Sinovac Biotechnology to investigate the safety, tolerability, and immunogenicity of different... Read More »
A new partnership announced last week between Integrum Scientific and the Coalition for Epidemic Preparedness Innovations (CEPI) will advance progress toward a Rift Valley fever (RVF) vaccine by developing an international antibody standard and validation of new assays.
From now until September... Read More »
BARDA’s Division of Research Innovation and Ventures (DRIVe) announced Thursday that it will partner with US Biologic Inc. to develop an oral vaccine for two strains of the influenza virus.
Part of BARDA DRIVe’s Beyond the Needle program, the partnership’s goal is to make vaccines and... Read More »
A Phase Three trial of Valneva SE’s chikungunya vaccine candidate, VLA1553, met with major success, according to topline results released last week that showed it induced protective neutralizing antibody titers in 98.5 percent of subjects after a single vaccination.
The trial involved 4,115... Read More »
Biotechnology company INOVIO dosed its first participant in a Phase 2 trial of a DNA vaccine for Middle East Respiratory Syndrome (MERS).
MERS, another coronavirus disease, is far deadlier than COVID-19, with a kill rate of approximately 34 percent. Fortunately, though, its transmission rate has... Read More »
A cocktail of casirivimab and imdevimab known as REGEN-COV, produced by Regeneron Pharmaceuticals, Inc., cut the risk of symptomatic infections by 81 percent in a Phase 3 trial of more than 1,500 people, according to a new publication in the New England Journal of Medicine.
Even better,... Read More »
A new report released this week by United States Sens. Rob Portman (R-OH) and Gary Peters (D-MI) revealed glaring cybersecurity failures at eight federal agencies over the past decade, along with the inability of seven of them to comply with basic cybersecurity requirements.
The Federal... Read More »
The U.S. Department of Homeland Security (DHS) Science and Technology Directorate (S&T) released its Artificial Intelligence & Machine Learning (AI/ML) Strategic Plan on Friday.
The proposed plan will incorporate the technological advancements in AI/ML to enhance the efficiency and... Read More »
Faced with a disease that tends to hit suddenly, erratically, and with extremely lethal effects, the Coalition for Epidemic Preparedness Innovations (CEPI) announced last week that it will provide up to $188,000 to support Universiti Malaya (UM) research into the Nipah virus.
UM, based in... Read More »
This year marks the fifth anniversary of the founding of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to funding and supporting the development of new products to counter antibiotic-resistant bacteria.
According to... Read More »
